Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Dooley

Showing results (211-220 of 263) with videos related to

Pageof 27
Sort By:
Antimicrobial Agents and Chemotherapy|July 15, 2015
Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimagingVincent P DeMarco, Alvaro A Ordonez, Mariah Klunk, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 8, 2016
Isoniazid hair concentrations in children with tuberculosis: a proof of concept studyV Mave, A Chandanwale, A Kinikar, et al.
JAMA Network Open|February 28, 2023
Analysis of Cardiorespiratory Fitness in Early Adulthood and Midlife With All-Cause Mortality and Fatal or Nonfatal Cardiovascular DiseaseKelley Pettee Gabriel, Byron C Jaeger, Cora E Lewis, et al.
Obesity (Silver Spring, Md.)|March 1, 2024
Transforming Big Data into AI-ready data for nutrition and obesity researchDiana M Thomas, Rob Knight, Jack A Gilbert, et al.
The Lancet. HIV|May 11, 2025
Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trialEthel D Weld, Trevor Beattie, Jayajothi Moodley, et al.
The Lancet. Infectious Diseases|February 15, 2021
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trialKelly E Dooley, Susan L Rosenkranz, Francesca Conradie, et al.
American Journal of Respiratory and Critical Care Medicine|August 17, 2021
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Xin Sun, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 1, 2021
Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomesV Mave, D Kadam, S Gaikwad, et al.
Progress in Nuclear Magnetic Resonance Spectroscopy|March 16, 2022
Mechanistic analysis by NMR spectroscopy: A users guideYael Ben-Tal, Patrick J Boaler, Harvey J A Dale, et al.
The European Respiratory Journal|February 5, 2021
Optimising pyrazinamide for the treatment of tuberculosisNan Zhang, Radojka M Savic, Martin J Boeree, et al.
Pageof 27

Showing results (211-220 of 263) with videos related to

Sort By:
Pageof 27
Antimicrobial Agents and Chemotherapy|July 15, 2015
Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimagingVincent P DeMarco, Alvaro A Ordonez, Mariah Klunk, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 8, 2016
Isoniazid hair concentrations in children with tuberculosis: a proof of concept studyV Mave, A Chandanwale, A Kinikar, et al.
JAMA Network Open|February 28, 2023
Analysis of Cardiorespiratory Fitness in Early Adulthood and Midlife With All-Cause Mortality and Fatal or Nonfatal Cardiovascular DiseaseKelley Pettee Gabriel, Byron C Jaeger, Cora E Lewis, et al.
Obesity (Silver Spring, Md.)|March 1, 2024
Transforming Big Data into AI-ready data for nutrition and obesity researchDiana M Thomas, Rob Knight, Jack A Gilbert, et al.
The Lancet. HIV|May 11, 2025
Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trialEthel D Weld, Trevor Beattie, Jayajothi Moodley, et al.
The Lancet. Infectious Diseases|February 15, 2021
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trialKelly E Dooley, Susan L Rosenkranz, Francesca Conradie, et al.
American Journal of Respiratory and Critical Care Medicine|August 17, 2021
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Xin Sun, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 1, 2021
Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomesV Mave, D Kadam, S Gaikwad, et al.
Progress in Nuclear Magnetic Resonance Spectroscopy|March 16, 2022
Mechanistic analysis by NMR spectroscopy: A users guideYael Ben-Tal, Patrick J Boaler, Harvey J A Dale, et al.
The European Respiratory Journal|February 5, 2021
Optimising pyrazinamide for the treatment of tuberculosisNan Zhang, Radojka M Savic, Martin J Boeree, et al.
Pageof 27